June 1, 2017 Ohio attorney general sues 5 drug companies related to opioid crisis The Ohio attorney general sued five drugmakers on Wednesday, accusing the companies of perpetrating the state's addictions epidemic by intentionally misleading patients about the dangers of painkillers and promoting benefits of the drugs not backed by science.
April 12, 2017 Opioids after surgery: Which patients don't stop when they should The first time many patients in the United States take prescription opioid painkillers is following surgery.
March 13, 2017 Few teens receive effective treatment for opioid addiction Just a small fraction of adolescents with opioid addiction will receive medications that can help them quit, new research shows.
March 10, 2017 Heroin’s grip: Families form support systems to deal with drug crisis The opioid crisis affects people from every socio-economic background in every state, afflicting every race, creed and color, from teenagers to senior citizens.
February 24, 2017 Strict limits on opioid prescribing risks the ‘inhumane treatment’ of pain patients Turning voluntary guidelines about prescribing opioids for chronic pain into strict policy will deny these medications to people who truly need them.
February 24, 2017 San Diego doctors see uptick in opioid-addicted newborns As America's addiction to painkillers reaches epidemic levels, the drugs are starting to affect San Diego's smallest and most vulnerable residents -- newborns.
February 24, 2017 Deadly US heroin overdoses quadrupled in five years: study The number of deadly heroin overdoses in the United States more than quadrupled from 2010 to 2015, a federal agency said on Friday, as the price of the drug dropped and its potency increased.
February 22, 2017 Opioids may be causing increase in cocaine overdoses The number of people dying from cocaine overdoses in the United States is on the rise, and a new study suggests why: People are using cocaine and opioids together.
February 21, 2017 FDA rejects Amphastar's nasal version of opioid overdose treatment Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the drug naloxone, which is designed to stop or reverse the effects of an opioid overdose.